Anavex Life Sciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 40
- Market Cap
- $515.5M
- Website
- http://www.anavex.com
- Introduction
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.
Playing The Odds Of Anavex Alzheimer's Drug Approval
Anavex's Alzheimer's drug Blarcamesine, with a 92% EMA approval likelihood, significantly slows cognitive decline by 36%. Expected approval by December 2025, it offers hope for Alzheimer's patients despite not addressing behavioral symptoms.
Anavex Life Sciences To Present At The 43Rd Annual J.P. Morgan Healthcare Conference
Anavex Life Sciences Corp. to present at the 43rd Annual Healthcare on January 16, 2025, in San Francisco. CEO Christopher U Missling will showcase the company's innovative treatments for CNS disorders, including Alzheimer's, Parkinson's, and Rett syndrome, highlighting ANAVEX®2-73 and ANAVEX®3-71's potential.
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Anavex Life Sciences Corp. to present at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025. The company focuses on treatments for CNS disorders, with ANAVEX®2-73 showing promise in clinical trials for Alzheimer's, Parkinson's, and Rett syndrome. ANAVEX®3-71 also demonstrates potential in preclinical Alzheimer's research.
HC Wainwright Has Optimistic Outlook of AVXL Q1 Earnings
HC Wainwright raised Anavex Life Sciences' Q1 2025 EPS estimate to ($0.17) from ($0.19), maintaining a 'Buy' rating with a $42 target. Anavex reported Q4 earnings of ($0.14), beating estimates by $0.03. Institutional investors increased stakes, with 31.55% of stock owned by them.
Anavex Life Sciences: Buy Rating Driven by European Approval Prospects and Strong Financial Position
Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Anavex Life Sciences, raising the price target to $42, citing the EMA's acceptance of blarcamesine's Marketing Authorization Application and the company's strong financial position.
Biotech Alert: Searches Spiking for These Stocks Today
Biotech stocks like Rapt Therapeutics, Sol-Gel Technologies, and Puma Biotechnology are seeing significant search interest surges, highlighting their focus on innovative treatments for diseases ranging from cancer to skin conditions.
H.C. Wainwright highlights blarcamesine's potential, raises Anavex stock target
H.C. Wainwright analyst raised Anavex Life Sciences' price target to $42, citing strong momentum and EMA's acceptance of blarcamesine for Alzheimer's treatment. Anavex shows robust financial health, with a market cap of $922M and a current ratio of 8.86. Blarcamesine's safety profile and cognitive benefits highlight its potential in the Alzheimer's treatment landscape.
Anavex Life Sciences Faces Manufacturing Challenges Impacting Product Launch
Anavex Life Sciences (AVXL) encounters manufacturing challenges, risking increased costs, delays, and potential impacts on product performance and regulatory approval, threatening its market launch and financial stability.
Earnings call transcript: Anavex Life Sciences Q4 2024 beats EPS forecast
Anavex Life Sciences reported Q4 2024 EPS of -$0.14, beating forecasts of -$0.1567. The stock surged 17.24% on positive investor sentiment. The company's progress in Alzheimer's and schizophrenia treatments, including EMA's acceptance of Blakamizant's marketing application, contributed to the strong performance.
© Copyright 2025. All Rights Reserved by MedPath